That's how i understand it too, with exceptions to the up-front payment to AMBS. I mean, it very well may be the case, i don't know, but many, it seems to me, think it's a given. If the CLIA partner is the same as the commercialization partner then up-front payments i believe are more likely because an actual JV will be established. If not, i see it no different than our partnership with BD, in one way or another, whether by agreeing upon a certain percentage of each test sale or by an actual up-front payment from AMBS to utilize their facilities, CLIA certification and expertise in bringing AMBS to FDA approval.

I don't know if I'm wrong or right or missing something altogether, im just failing to see how one can expect any up-front payment from a CLIA only partner. Splitting revenue, i can see happening but why is an up-front payment a given at this point pre FDA approval? Yes, we have a sweet product on our hands but it still needs to be developed and approved...we need them as much as they probably want us.